Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 2, 2010
Business Overview: IRIDEX is a provider of therapeutic laser systems and delivery devices for ophthalmology and aesthetics. The company operates in two reportable segments: Ophthalmology and Aesthetics. In April 2010, the company acquired substantially all assets of RetinaLabs, Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Oct 2, 2010 | Nine Months Ended Oct 2, 2010 | Nine Months Ended Oct 3, 2009 |
|---|---|---|---|
| Total Revenues | $10,818 | $31,466 | $31,649 |
| Gross Profit | $5,249 | $15,010 | $14,999 |
| Gross Margin | 48.5% | 47.7% | 47.4% |
| Net Income | $910 | $2,209 | $2,068 |
| Diluted EPS | $0.09 | $0.22 | $0.21 |
| Cash and Equivalents (Oct 2, 2010) | $7,092 | ||
| Working Capital (Oct 2, 2010) | $16,057 | ||
| Debt Outstanding | $0 (Revolving credit facility available but unused) |
Material Changes vs. Prior Period
- Revenue: Total revenue increased 4.0% year-over-year for the quarter ($10.8M vs $10.4M) but decreased slightly for the nine-month period ($31.5M vs $31.6M).
- Ophthalmology: Revenues increased 5.8% for the quarter and 3.9% for the nine months, driven by domestic system sales (including a $0.5M US Military order) and international growth.
- Aesthetics: Revenues increased 5.1% for the quarter but declined 6.2% for the nine months, primarily due to a decrease in service revenues.
- OEM: Revenues declined significantly (52.2% for the quarter) as the product reaches end-of-life.
- Profitability: Net income increased 40.9% for the quarter ($0.91M vs $0.65M) and 6.8% for the nine months ($2.21M vs $2.07M). The nine-month period included a one-time legal settlement gain of $0.8M in the prior year which was not present in the current year, yet net income still improved.
- Operating Expenses: R&D expenses increased 10.6% for the nine months due to headcount and material costs. General and administrative expenses decreased 9.7% for the nine months.
- Liquidity: The company repaid its previous bank debt in Q1 2010 and entered a new $5.0M revolving credit facility with Silicon Valley Bank in Q2 2010, which currently has no outstanding balance.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash, operating cash flows, and the new credit facility provide sufficient liquidity for the next 12 months. The company expects to continue increasing R&D spending to support new product introductions.
- Acquisition Impact: The RetinaLabs acquisition (April 2010) has not yet had a significant impact on results of operations. The purchase price included cash, stock, and an earn-out tied to future revenues.
- Risks and Contingencies:
- Market Acceptance: Reliance on continued sales of existing products and market acceptance of new applications.
- Healthcare Reform: Potential adverse effects from the Patient Protection and Affordable Care Act (PPACA) on reimbursement rates and procedure volumes.
- International Exposure: Approximately 40% of revenue is international; a stronger US dollar could reduce competitiveness.
- Patent Expiration: The "Connector Patent" protecting consumable EndoProbe devices expires in the second half of 2010, potentially increasing competition.
- Supply Chain: Dependence on sole or limited source suppliers for critical components.
Investor Verification Checklist
- Recurring Revenue Trends: Verify the sustainability of the first eight-quarter increase in ophthalmology recurring revenues (consumables and service).
- OEM Decline: Assess the timeline and financial impact of the declining OEM revenue stream from the Bausch & Lomb partnership.
- Patent Expiration: Evaluate the competitive landscape and pricing power for consumable EndoProbe devices following the expiration of the Connector Patent in late 2010.
- RetinaLabs Integration: Monitor the performance of RetinaLabs products against the earn-out targets to determine future cash and stock obligations.
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive to support operations without drawing on the new $5M credit facility.